头颈部鳞状细胞癌中的表皮生长因子受体抑制作用
Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
作者信息
Machiels Jean-Pascal, Schmitz Sandra
机构信息
Departments of Medical Oncology and Head and Neck Surgery, King Albert II Institute, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC), Université catholique de Louvain, 10 avenue Hippocrate, Brussels 1200, Belgium.
Departments of Medical Oncology and Head and Neck Surgery, King Albert II Institute, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC), Université catholique de Louvain, 10 avenue Hippocrate, Brussels 1200, Belgium.
出版信息
Hematol Oncol Clin North Am. 2015 Dec;29(6):1011-32. doi: 10.1016/j.hoc.2015.07.007.
Overexpression of epidermal growth factor receptor (EGFR) is linked with poor prognosis in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab binds specifically to EGFR with high affinity; combined with radiotherapy, it improves locoregional control and survival over radiotherapy alone. Adding cetuximab to platinum-based chemotherapy and 5-fluorouracil improves overall survival in incurable disease. Only a minority of patients benefit from anti-EGFR monoclonal antibodies. A better understanding of the molecular mechanisms involved in treatment resistance and identification of predictive biomarkers are crucial. Potentially more potent anti-EGFR compounds are currently under investigation with the aim of improving treatment efficacy.
表皮生长因子受体（EGFR）的过表达与头颈部鳞状细胞癌（SCCHN）的预后不良有关。西妥昔单抗以高亲和力特异性结合EGFR；与放疗联合使用时，与单纯放疗相比，它可改善局部区域控制并提高生存率。在铂类化疗和5-氟尿嘧啶中添加西妥昔单抗可提高不可治愈疾病的总生存率。只有少数患者能从抗EGFR单克隆抗体中获益。更好地理解治疗耐药所涉及的分子机制并鉴定预测性生物标志物至关重要。目前正在研究潜在效力更强的抗EGFR化合物，目的是提高治疗效果。
Zotero 插件